Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.390
+0.020 (0.46%)
At close: Jul 24, 2026, 4:00 PM EDT
4.420
+0.030 (0.68%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$798,576
Market Cap
5.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | -4 | -10.81% |
| Dec 31, 2024 | 37 | -3 | -7.50% |
| Dec 31, 2023 | 40 | -5 | -11.11% |
| Dec 31, 2022 | 45 | -9 | -16.67% |
| Dec 31, 2021 | 54 | -4 | -6.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| AIM ImmunoTech | 21 |
| Soligenix | 14 |
| NuCana | 12 |
| Purple Biotech | 10 |
| Adial Pharmaceuticals | 5 |
APVO News
- 25 days ago - Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund - TheFly
- 25 days ago - Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - Accesswire
- 2 months ago - Aptevo Therapeutics appoints Janatpour as SVP, CSO - TheFly
- 2 months ago - Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D. - Accesswire
- 2 months ago - Aptevo, Niowave launch collab for radiopharmaceutical oncology programs - TheFly
- 2 months ago - Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Accesswire
- 2 months ago - Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M - TheFly
- 2 months ago - Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire